nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—ORM1—Vismodegib—skin cancer	0.234	0.317	CbGbCtD
Maprotiline—ORM1—Vemurafenib—skin cancer	0.185	0.251	CbGbCtD
Maprotiline—CYP1A2—Imiquimod—skin cancer	0.0849	0.115	CbGbCtD
Maprotiline—ABCB1—Vismodegib—skin cancer	0.0515	0.0698	CbGbCtD
Maprotiline—CYP1A2—Vemurafenib—skin cancer	0.0465	0.0631	CbGbCtD
Maprotiline—CYP2D6—Vemurafenib—skin cancer	0.0383	0.052	CbGbCtD
Maprotiline—CYP1A2—Dacarbazine—skin cancer	0.0357	0.0484	CbGbCtD
Maprotiline—ABCB1—Dactinomycin—skin cancer	0.027	0.0367	CbGbCtD
Maprotiline—CYP1A2—Fluorouracil—skin cancer	0.0209	0.0283	CbGbCtD
Maprotiline—ABCB1—Docetaxel—skin cancer	0.014	0.0189	CbGbCtD
Maprotiline—CHRM3—muscle of abdomen—skin cancer	0.00722	0.11	CbGeAlD
Maprotiline—HRH1—nose—skin cancer	0.00558	0.0851	CbGeAlD
Maprotiline—CHRM5—skin epidermis—skin cancer	0.00472	0.0721	CbGeAlD
Maprotiline—SLC6A3—nerve—skin cancer	0.00275	0.042	CbGeAlD
Maprotiline—SLC6A2—nerve—skin cancer	0.00222	0.0339	CbGeAlD
Maprotiline—HTR2A—hindlimb—skin cancer	0.00219	0.0335	CbGeAlD
Maprotiline—HTR7—nerve—skin cancer	0.00214	0.0327	CbGeAlD
Maprotiline—DRD2—nerve—skin cancer	0.00202	0.0309	CbGeAlD
Maprotiline—HTR2A—appendage—skin cancer	0.00188	0.0287	CbGeAlD
Maprotiline—HTR7—endothelium—skin cancer	0.00182	0.0278	CbGeAlD
Maprotiline—HTR7—blood vessel—skin cancer	0.00168	0.0257	CbGeAlD
Maprotiline—CHRM5—epithelium—skin cancer	0.00154	0.0235	CbGeAlD
Maprotiline—CHRM5—skin of body—skin cancer	0.00146	0.0223	CbGeAlD
Maprotiline—HTR2A—nerve—skin cancer	0.00133	0.0204	CbGeAlD
Maprotiline—CHRM4—head—skin cancer	0.00122	0.0186	CbGeAlD
Maprotiline—HTR7—neck—skin cancer	0.0012	0.0184	CbGeAlD
Maprotiline—HTR2A—endothelium—skin cancer	0.00114	0.0174	CbGeAlD
Maprotiline—HTR2A—blood vessel—skin cancer	0.00105	0.016	CbGeAlD
Maprotiline—CYP1A2—nipple—skin cancer	0.000969	0.0148	CbGeAlD
Maprotiline—CHRM5—head—skin cancer	0.000954	0.0146	CbGeAlD
Maprotiline—HRH1—nipple—skin cancer	0.000907	0.0139	CbGeAlD
Maprotiline—HTR7—connective tissue—skin cancer	0.000862	0.0132	CbGeAlD
Maprotiline—ORM1—female reproductive system—skin cancer	0.00084	0.0128	CbGeAlD
Maprotiline—HTR7—epithelium—skin cancer	0.000818	0.0125	CbGeAlD
Maprotiline—HTR2C—female reproductive system—skin cancer	0.000755	0.0115	CbGeAlD
Maprotiline—HTR2A—neck—skin cancer	0.00075	0.0114	CbGeAlD
Maprotiline—CHRM1—female reproductive system—skin cancer	0.000713	0.0109	CbGeAlD
Maprotiline—ABCB1—blood vessel—skin cancer	0.000687	0.0105	CbGeAlD
Maprotiline—CHRM2—head—skin cancer	0.000655	0.01	CbGeAlD
Maprotiline—SLC6A3—head—skin cancer	0.000653	0.00997	CbGeAlD
Maprotiline—HRH1—connective tissue—skin cancer	0.000643	0.00982	CbGeAlD
Maprotiline—CHRM3—female reproductive system—skin cancer	0.000638	0.00975	CbGeAlD
Maprotiline—HTR2C—head—skin cancer	0.000631	0.00964	CbGeAlD
Maprotiline—SLC6A2—female reproductive system—skin cancer	0.000631	0.00963	CbGeAlD
Maprotiline—HRH1—epithelium—skin cancer	0.000611	0.00933	CbGeAlD
Maprotiline—HTR7—female reproductive system—skin cancer	0.000608	0.00928	CbGeAlD
Maprotiline—CHRM1—head—skin cancer	0.000596	0.0091	CbGeAlD
Maprotiline—HTR2A—connective tissue—skin cancer	0.000537	0.0082	CbGeAlD
Maprotiline—CHRM3—head—skin cancer	0.000533	0.00814	CbGeAlD
Maprotiline—HRH1—mammalian vulva—skin cancer	0.00053	0.00809	CbGeAlD
Maprotiline—SLC6A2—head—skin cancer	0.000527	0.00804	CbGeAlD
Maprotiline—Muscular weakness—Fluorouracil—skin cancer	0.000519	0.00271	CcSEcCtD
Maprotiline—Shock—Imiquimod—skin cancer	0.000515	0.00269	CcSEcCtD
Maprotiline—Nervous system disorder—Imiquimod—skin cancer	0.000513	0.00269	CcSEcCtD
Maprotiline—Tachycardia—Imiquimod—skin cancer	0.000511	0.00267	CcSEcCtD
Maprotiline—HTR2A—epithelium—skin cancer	0.00051	0.00779	CbGeAlD
Maprotiline—Pollakiuria—Temozolomide—skin cancer	0.00051	0.00267	CcSEcCtD
Maprotiline—Skin disorder—Imiquimod—skin cancer	0.000508	0.00266	CcSEcCtD
Maprotiline—Dysphagia—Fluorouracil—skin cancer	0.000508	0.00266	CcSEcCtD
Maprotiline—Erectile dysfunction—Temozolomide—skin cancer	0.000508	0.00266	CcSEcCtD
Maprotiline—HTR7—head—skin cancer	0.000508	0.00775	CbGeAlD
Maprotiline—Agranulocytosis—Dactinomycin—skin cancer	0.000507	0.00265	CcSEcCtD
Maprotiline—Hyperhidrosis—Imiquimod—skin cancer	0.000506	0.00265	CcSEcCtD
Maprotiline—Photosensitivity reaction—Temozolomide—skin cancer	0.000503	0.00263	CcSEcCtD
Maprotiline—Eosinophilia—Fluorouracil—skin cancer	0.000503	0.00263	CcSEcCtD
Maprotiline—Weight increased—Temozolomide—skin cancer	0.000502	0.00263	CcSEcCtD
Maprotiline—Weight decreased—Temozolomide—skin cancer	0.000499	0.00261	CcSEcCtD
Maprotiline—Infestation—Temozolomide—skin cancer	0.000492	0.00257	CcSEcCtD
Maprotiline—Infestation NOS—Temozolomide—skin cancer	0.000492	0.00257	CcSEcCtD
Maprotiline—ORM1—lymph node—skin cancer	0.000492	0.00751	CbGeAlD
Maprotiline—Hepatitis—Dactinomycin—skin cancer	0.000488	0.00255	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000488	0.00255	CcSEcCtD
Maprotiline—Flushing—Bleomycin—skin cancer	0.000486	0.00254	CcSEcCtD
Maprotiline—Body temperature increased—Vemurafenib—skin cancer	0.000485	0.00254	CcSEcCtD
Maprotiline—Pancytopenia—Fluorouracil—skin cancer	0.000483	0.00253	CcSEcCtD
Maprotiline—Neuropathy peripheral—Temozolomide—skin cancer	0.000482	0.00252	CcSEcCtD
Maprotiline—DRD2—head—skin cancer	0.00048	0.00733	CbGeAlD
Maprotiline—Stomatitis—Temozolomide—skin cancer	0.000479	0.00251	CcSEcCtD
Maprotiline—Insomnia—Imiquimod—skin cancer	0.000473	0.00248	CcSEcCtD
Maprotiline—Paraesthesia—Imiquimod—skin cancer	0.00047	0.00246	CcSEcCtD
Maprotiline—Somnolence—Imiquimod—skin cancer	0.000465	0.00243	CcSEcCtD
Maprotiline—Hepatobiliary disease—Temozolomide—skin cancer	0.000465	0.00243	CcSEcCtD
Maprotiline—Photosensitivity reaction—Fluorouracil—skin cancer	0.000464	0.00243	CcSEcCtD
Maprotiline—Alopecia—Bleomycin—skin cancer	0.000462	0.00242	CcSEcCtD
Maprotiline—Erythema multiforme—Dactinomycin—skin cancer	0.000462	0.00241	CcSEcCtD
Maprotiline—Dyspepsia—Imiquimod—skin cancer	0.000461	0.00241	CcSEcCtD
Maprotiline—HRH1—female reproductive system—skin cancer	0.000454	0.00693	CbGeAlD
Maprotiline—Hot flush—Docetaxel—skin cancer	0.000454	0.00237	CcSEcCtD
Maprotiline—Infestation NOS—Fluorouracil—skin cancer	0.000453	0.00237	CcSEcCtD
Maprotiline—Infestation—Fluorouracil—skin cancer	0.000453	0.00237	CcSEcCtD
Maprotiline—Flushing—Dactinomycin—skin cancer	0.000453	0.00237	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Imiquimod—skin cancer	0.000452	0.00236	CcSEcCtD
Maprotiline—Fatigue—Imiquimod—skin cancer	0.000451	0.00236	CcSEcCtD
Maprotiline—Menopausal symptoms—Docetaxel—skin cancer	0.00045	0.00235	CcSEcCtD
Maprotiline—Acute coronary syndrome—Fluorouracil—skin cancer	0.000447	0.00234	CcSEcCtD
Maprotiline—Myocardial infarction—Fluorouracil—skin cancer	0.000444	0.00232	CcSEcCtD
Maprotiline—Neuropathy peripheral—Fluorouracil—skin cancer	0.000444	0.00232	CcSEcCtD
Maprotiline—Stomatitis—Fluorouracil—skin cancer	0.000442	0.00231	CcSEcCtD
Maprotiline—Hepatitis—Temozolomide—skin cancer	0.000441	0.00231	CcSEcCtD
Maprotiline—Asthenia—Vemurafenib—skin cancer	0.00044	0.0023	CcSEcCtD
Maprotiline—Hypoaesthesia—Temozolomide—skin cancer	0.000439	0.0023	CcSEcCtD
Maprotiline—Hallucination—Temozolomide—skin cancer	0.000439	0.0023	CcSEcCtD
Maprotiline—Urinary tract disorder—Temozolomide—skin cancer	0.000436	0.00228	CcSEcCtD
Maprotiline—Pruritus—Vemurafenib—skin cancer	0.000434	0.00227	CcSEcCtD
Maprotiline—Urethral disorder—Temozolomide—skin cancer	0.000433	0.00226	CcSEcCtD
Maprotiline—Alopecia—Dactinomycin—skin cancer	0.000431	0.00226	CcSEcCtD
Maprotiline—Feeling abnormal—Imiquimod—skin cancer	0.000431	0.00226	CcSEcCtD
Maprotiline—Gastrointestinal pain—Imiquimod—skin cancer	0.000428	0.00224	CcSEcCtD
Maprotiline—Agranulocytosis—Fluorouracil—skin cancer	0.000423	0.00221	CcSEcCtD
Maprotiline—Diarrhoea—Vemurafenib—skin cancer	0.00042	0.0022	CcSEcCtD
Maprotiline—Erythema multiforme—Temozolomide—skin cancer	0.000417	0.00218	CcSEcCtD
Maprotiline—Urticaria—Imiquimod—skin cancer	0.000416	0.00218	CcSEcCtD
Maprotiline—Body temperature increased—Imiquimod—skin cancer	0.000414	0.00216	CcSEcCtD
Maprotiline—Abdominal pain—Imiquimod—skin cancer	0.000414	0.00216	CcSEcCtD
Maprotiline—Eye disorder—Temozolomide—skin cancer	0.000413	0.00216	CcSEcCtD
Maprotiline—Tinnitus—Temozolomide—skin cancer	0.000412	0.00215	CcSEcCtD
Maprotiline—Flushing—Temozolomide—skin cancer	0.00041	0.00214	CcSEcCtD
Maprotiline—Cardiac disorder—Temozolomide—skin cancer	0.00041	0.00214	CcSEcCtD
Maprotiline—Leukopenia—Bleomycin—skin cancer	0.000408	0.00213	CcSEcCtD
Maprotiline—Dizziness—Vemurafenib—skin cancer	0.000406	0.00212	CcSEcCtD
Maprotiline—Hypoaesthesia—Fluorouracil—skin cancer	0.000405	0.00212	CcSEcCtD
Maprotiline—Angiopathy—Temozolomide—skin cancer	0.000401	0.0021	CcSEcCtD
Maprotiline—Ataxia—Docetaxel—skin cancer	0.000399	0.00209	CcSEcCtD
Maprotiline—Mediastinal disorder—Temozolomide—skin cancer	0.000398	0.00208	CcSEcCtD
Maprotiline—Liver function test abnormal—Docetaxel—skin cancer	0.000392	0.00205	CcSEcCtD
Maprotiline—Vomiting—Vemurafenib—skin cancer	0.00039	0.00204	CcSEcCtD
Maprotiline—Alopecia—Temozolomide—skin cancer	0.00039	0.00204	CcSEcCtD
Maprotiline—Orthostatic hypotension—Docetaxel—skin cancer	0.000388	0.00203	CcSEcCtD
Maprotiline—Rash—Vemurafenib—skin cancer	0.000387	0.00202	CcSEcCtD
Maprotiline—Dermatitis—Vemurafenib—skin cancer	0.000387	0.00202	CcSEcCtD
Maprotiline—Headache—Vemurafenib—skin cancer	0.000384	0.00201	CcSEcCtD
Maprotiline—Malnutrition—Temozolomide—skin cancer	0.000384	0.00201	CcSEcCtD
Maprotiline—Breast disorder—Docetaxel—skin cancer	0.000384	0.00201	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000382	0.002	CcSEcCtD
Maprotiline—Leukopenia—Dactinomycin—skin cancer	0.00038	0.00199	CcSEcCtD
Maprotiline—HRH1—head—skin cancer	0.000379	0.00579	CbGeAlD
Maprotiline—HTR2A—female reproductive system—skin cancer	0.000379	0.00579	CbGeAlD
Maprotiline—Dysgeusia—Temozolomide—skin cancer	0.000376	0.00197	CcSEcCtD
Maprotiline—Asthenia—Imiquimod—skin cancer	0.000376	0.00196	CcSEcCtD
Maprotiline—Confusional state—Bleomycin—skin cancer	0.000375	0.00196	CcSEcCtD
Maprotiline—Oedema—Bleomycin—skin cancer	0.000372	0.00195	CcSEcCtD
Maprotiline—Pruritus—Imiquimod—skin cancer	0.00037	0.00194	CcSEcCtD
Maprotiline—Infection—Bleomycin—skin cancer	0.000369	0.00193	CcSEcCtD
Maprotiline—SLC6A2—lymph node—skin cancer	0.000369	0.00563	CbGeAlD
Maprotiline—Dysphagia—Docetaxel—skin cancer	0.000367	0.00192	CcSEcCtD
Maprotiline—Nausea—Vemurafenib—skin cancer	0.000365	0.00191	CcSEcCtD
Maprotiline—Thrombocytopenia—Bleomycin—skin cancer	0.000364	0.0019	CcSEcCtD
Maprotiline—Arrhythmia—Fluorouracil—skin cancer	0.000363	0.0019	CcSEcCtD
Maprotiline—Vision blurred—Temozolomide—skin cancer	0.000362	0.0019	CcSEcCtD
Maprotiline—Bronchospasm—Docetaxel—skin cancer	0.000361	0.00189	CcSEcCtD
Maprotiline—Tremor—Temozolomide—skin cancer	0.00036	0.00188	CcSEcCtD
Maprotiline—Alopecia—Fluorouracil—skin cancer	0.000359	0.00188	CcSEcCtD
Maprotiline—Diarrhoea—Imiquimod—skin cancer	0.000358	0.00187	CcSEcCtD
Maprotiline—Agitation—Temozolomide—skin cancer	0.000353	0.00185	CcSEcCtD
Maprotiline—Pancytopenia—Docetaxel—skin cancer	0.000348	0.00182	CcSEcCtD
Maprotiline—Hypotension—Bleomycin—skin cancer	0.000347	0.00182	CcSEcCtD
Maprotiline—Oedema—Dactinomycin—skin cancer	0.000347	0.00181	CcSEcCtD
Maprotiline—Dizziness—Imiquimod—skin cancer	0.000346	0.00181	CcSEcCtD
Maprotiline—CYP2D6—female reproductive system—skin cancer	0.000345	0.00527	CbGeAlD
Maprotiline—Infection—Dactinomycin—skin cancer	0.000345	0.0018	CcSEcCtD
Maprotiline—Leukopenia—Temozolomide—skin cancer	0.000344	0.0018	CcSEcCtD
Maprotiline—Palpitations—Temozolomide—skin cancer	0.00034	0.00178	CcSEcCtD
Maprotiline—Thrombocytopenia—Dactinomycin—skin cancer	0.00034	0.00178	CcSEcCtD
Maprotiline—ABCB1—epithelium—skin cancer	0.000334	0.0051	CbGeAlD
Maprotiline—Paraesthesia—Bleomycin—skin cancer	0.000334	0.00175	CcSEcCtD
Maprotiline—Weight increased—Docetaxel—skin cancer	0.000334	0.00175	CcSEcCtD
Maprotiline—Vision blurred—Fluorouracil—skin cancer	0.000334	0.00175	CcSEcCtD
Maprotiline—Convulsion—Temozolomide—skin cancer	0.000333	0.00174	CcSEcCtD
Maprotiline—Vomiting—Imiquimod—skin cancer	0.000333	0.00174	CcSEcCtD
Maprotiline—Weight decreased—Docetaxel—skin cancer	0.000332	0.00174	CcSEcCtD
Maprotiline—Hypertension—Temozolomide—skin cancer	0.000332	0.00174	CcSEcCtD
Maprotiline—Rash—Imiquimod—skin cancer	0.00033	0.00173	CcSEcCtD
Maprotiline—Dermatitis—Imiquimod—skin cancer	0.00033	0.00173	CcSEcCtD
Maprotiline—Headache—Imiquimod—skin cancer	0.000328	0.00172	CcSEcCtD
Maprotiline—Infestation NOS—Docetaxel—skin cancer	0.000327	0.00171	CcSEcCtD
Maprotiline—Infestation—Docetaxel—skin cancer	0.000327	0.00171	CcSEcCtD
Maprotiline—Anxiety—Temozolomide—skin cancer	0.000326	0.00171	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000325	0.0017	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000324	0.0017	CcSEcCtD
Maprotiline—Acute coronary syndrome—Docetaxel—skin cancer	0.000322	0.00169	CcSEcCtD
Maprotiline—Myocardial infarction—Docetaxel—skin cancer	0.000321	0.00168	CcSEcCtD
Maprotiline—Neuropathy peripheral—Docetaxel—skin cancer	0.000321	0.00168	CcSEcCtD
Maprotiline—Dry mouth—Temozolomide—skin cancer	0.00032	0.00167	CcSEcCtD
Maprotiline—Stomatitis—Docetaxel—skin cancer	0.000319	0.00167	CcSEcCtD
Maprotiline—Jaundice—Docetaxel—skin cancer	0.000319	0.00167	CcSEcCtD
Maprotiline—Leukopenia—Fluorouracil—skin cancer	0.000317	0.00166	CcSEcCtD
Maprotiline—HTR2A—head—skin cancer	0.000317	0.00483	CbGeAlD
Maprotiline—Confusional state—Temozolomide—skin cancer	0.000316	0.00165	CcSEcCtD
Maprotiline—Oedema—Temozolomide—skin cancer	0.000314	0.00164	CcSEcCtD
Maprotiline—Infection—Temozolomide—skin cancer	0.000312	0.00163	CcSEcCtD
Maprotiline—Nausea—Imiquimod—skin cancer	0.000311	0.00163	CcSEcCtD
Maprotiline—Hepatobiliary disease—Docetaxel—skin cancer	0.000309	0.00162	CcSEcCtD
Maprotiline—Nervous system disorder—Temozolomide—skin cancer	0.000308	0.00161	CcSEcCtD
Maprotiline—Thrombocytopenia—Temozolomide—skin cancer	0.000307	0.00161	CcSEcCtD
Maprotiline—Convulsion—Fluorouracil—skin cancer	0.000307	0.00161	CcSEcCtD
Maprotiline—Feeling abnormal—Bleomycin—skin cancer	0.000306	0.0016	CcSEcCtD
Maprotiline—Agranulocytosis—Docetaxel—skin cancer	0.000305	0.0016	CcSEcCtD
Maprotiline—Skin disorder—Temozolomide—skin cancer	0.000305	0.00159	CcSEcCtD
Maprotiline—Hyperhidrosis—Temozolomide—skin cancer	0.000303	0.00159	CcSEcCtD
Maprotiline—Fatigue—Dactinomycin—skin cancer	0.000299	0.00156	CcSEcCtD
Maprotiline—Urticaria—Bleomycin—skin cancer	0.000295	0.00155	CcSEcCtD
Maprotiline—Body temperature increased—Bleomycin—skin cancer	0.000294	0.00154	CcSEcCtD
Maprotiline—Hepatitis—Docetaxel—skin cancer	0.000294	0.00154	CcSEcCtD
Maprotiline—Hypoaesthesia—Docetaxel—skin cancer	0.000292	0.00153	CcSEcCtD
Maprotiline—Confusional state—Fluorouracil—skin cancer	0.000291	0.00152	CcSEcCtD
Maprotiline—ABCB1—mammalian vulva—skin cancer	0.00029	0.00443	CbGeAlD
Maprotiline—Urinary tract disorder—Docetaxel—skin cancer	0.00029	0.00152	CcSEcCtD
Maprotiline—Oedema—Fluorouracil—skin cancer	0.000289	0.00151	CcSEcCtD
Maprotiline—CYP2D6—head—skin cancer	0.000288	0.0044	CbGeAlD
Maprotiline—Urethral disorder—Docetaxel—skin cancer	0.000288	0.00151	CcSEcCtD
Maprotiline—Infection—Fluorouracil—skin cancer	0.000287	0.0015	CcSEcCtD
Maprotiline—Feeling abnormal—Dactinomycin—skin cancer	0.000286	0.0015	CcSEcCtD
Maprotiline—Insomnia—Temozolomide—skin cancer	0.000284	0.00148	CcSEcCtD
Maprotiline—Gastrointestinal pain—Dactinomycin—skin cancer	0.000284	0.00148	CcSEcCtD
Maprotiline—Nervous system disorder—Fluorouracil—skin cancer	0.000283	0.00148	CcSEcCtD
Maprotiline—Thrombocytopenia—Fluorouracil—skin cancer	0.000283	0.00148	CcSEcCtD
Maprotiline—Tachycardia—Fluorouracil—skin cancer	0.000282	0.00148	CcSEcCtD
Maprotiline—Paraesthesia—Temozolomide—skin cancer	0.000282	0.00147	CcSEcCtD
Maprotiline—Somnolence—Temozolomide—skin cancer	0.000279	0.00146	CcSEcCtD
Maprotiline—Erythema multiforme—Docetaxel—skin cancer	0.000278	0.00145	CcSEcCtD
Maprotiline—Dyspepsia—Temozolomide—skin cancer	0.000276	0.00144	CcSEcCtD
Maprotiline—Eye disorder—Docetaxel—skin cancer	0.000274	0.00144	CcSEcCtD
Maprotiline—Abdominal pain—Dactinomycin—skin cancer	0.000274	0.00143	CcSEcCtD
Maprotiline—Body temperature increased—Dactinomycin—skin cancer	0.000274	0.00143	CcSEcCtD
Maprotiline—Flushing—Docetaxel—skin cancer	0.000272	0.00143	CcSEcCtD
Maprotiline—Cardiac disorder—Docetaxel—skin cancer	0.000272	0.00143	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Temozolomide—skin cancer	0.000271	0.00142	CcSEcCtD
Maprotiline—Fatigue—Temozolomide—skin cancer	0.00027	0.00141	CcSEcCtD
Maprotiline—Hypotension—Fluorouracil—skin cancer	0.00027	0.00141	CcSEcCtD
Maprotiline—Constipation—Temozolomide—skin cancer	0.000268	0.0014	CcSEcCtD
Maprotiline—Asthenia—Bleomycin—skin cancer	0.000267	0.0014	CcSEcCtD
Maprotiline—Angiopathy—Docetaxel—skin cancer	0.000266	0.00139	CcSEcCtD
Maprotiline—HRH1—lymph node—skin cancer	0.000265	0.00405	CbGeAlD
Maprotiline—Mediastinal disorder—Docetaxel—skin cancer	0.000265	0.00138	CcSEcCtD
Maprotiline—Pruritus—Bleomycin—skin cancer	0.000263	0.00138	CcSEcCtD
Maprotiline—Arrhythmia—Docetaxel—skin cancer	0.000262	0.00137	CcSEcCtD
Maprotiline—Insomnia—Fluorouracil—skin cancer	0.000261	0.00137	CcSEcCtD
Maprotiline—Paraesthesia—Fluorouracil—skin cancer	0.000259	0.00136	CcSEcCtD
Maprotiline—Alopecia—Docetaxel—skin cancer	0.000259	0.00136	CcSEcCtD
Maprotiline—Feeling abnormal—Temozolomide—skin cancer	0.000258	0.00135	CcSEcCtD
Maprotiline—ABCB1—lymphoid tissue—skin cancer	0.000257	0.00393	CbGeAlD
Maprotiline—Somnolence—Fluorouracil—skin cancer	0.000257	0.00134	CcSEcCtD
Maprotiline—Gastrointestinal pain—Temozolomide—skin cancer	0.000256	0.00134	CcSEcCtD
Maprotiline—Malnutrition—Docetaxel—skin cancer	0.000256	0.00134	CcSEcCtD
Maprotiline—Dyspepsia—Fluorouracil—skin cancer	0.000254	0.00133	CcSEcCtD
Maprotiline—Dysgeusia—Docetaxel—skin cancer	0.00025	0.00131	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000249	0.00131	CcSEcCtD
Maprotiline—Urticaria—Temozolomide—skin cancer	0.000249	0.0013	CcSEcCtD
Maprotiline—Asthenia—Dactinomycin—skin cancer	0.000249	0.0013	CcSEcCtD
Maprotiline—ABCB1—female reproductive system—skin cancer	0.000248	0.00379	CbGeAlD
Maprotiline—Abdominal pain—Temozolomide—skin cancer	0.000248	0.0013	CcSEcCtD
Maprotiline—Body temperature increased—Temozolomide—skin cancer	0.000248	0.0013	CcSEcCtD
Maprotiline—Feeling abnormal—Fluorouracil—skin cancer	0.000238	0.00125	CcSEcCtD
Maprotiline—Diarrhoea—Dactinomycin—skin cancer	0.000237	0.00124	CcSEcCtD
Maprotiline—Vomiting—Bleomycin—skin cancer	0.000236	0.00124	CcSEcCtD
Maprotiline—Rash—Bleomycin—skin cancer	0.000234	0.00123	CcSEcCtD
Maprotiline—Dermatitis—Bleomycin—skin cancer	0.000234	0.00123	CcSEcCtD
Maprotiline—Urticaria—Fluorouracil—skin cancer	0.00023	0.0012	CcSEcCtD
Maprotiline—Syncope—Docetaxel—skin cancer	0.000229	0.0012	CcSEcCtD
Maprotiline—Leukopenia—Docetaxel—skin cancer	0.000229	0.0012	CcSEcCtD
Maprotiline—Body temperature increased—Fluorouracil—skin cancer	0.000228	0.0012	CcSEcCtD
Maprotiline—Palpitations—Docetaxel—skin cancer	0.000226	0.00118	CcSEcCtD
Maprotiline—Asthenia—Temozolomide—skin cancer	0.000225	0.00118	CcSEcCtD
Maprotiline—Loss of consciousness—Docetaxel—skin cancer	0.000225	0.00118	CcSEcCtD
Maprotiline—Pruritus—Temozolomide—skin cancer	0.000222	0.00116	CcSEcCtD
Maprotiline—Convulsion—Docetaxel—skin cancer	0.000221	0.00116	CcSEcCtD
Maprotiline—Nausea—Bleomycin—skin cancer	0.000221	0.00116	CcSEcCtD
Maprotiline—Hypertension—Docetaxel—skin cancer	0.000221	0.00115	CcSEcCtD
Maprotiline—Vomiting—Dactinomycin—skin cancer	0.00022	0.00115	CcSEcCtD
Maprotiline—Rash—Dactinomycin—skin cancer	0.000219	0.00114	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000216	0.00113	CcSEcCtD
Maprotiline—Diarrhoea—Temozolomide—skin cancer	0.000215	0.00112	CcSEcCtD
Maprotiline—Dry mouth—Docetaxel—skin cancer	0.000213	0.00111	CcSEcCtD
Maprotiline—Confusional state—Docetaxel—skin cancer	0.00021	0.0011	CcSEcCtD
Maprotiline—Oedema—Docetaxel—skin cancer	0.000209	0.00109	CcSEcCtD
Maprotiline—ABCB1—head—skin cancer	0.000207	0.00317	CbGeAlD
Maprotiline—Dizziness—Temozolomide—skin cancer	0.000207	0.00109	CcSEcCtD
Maprotiline—Infection—Docetaxel—skin cancer	0.000207	0.00108	CcSEcCtD
Maprotiline—Nausea—Dactinomycin—skin cancer	0.000206	0.00108	CcSEcCtD
Maprotiline—Shock—Docetaxel—skin cancer	0.000205	0.00107	CcSEcCtD
Maprotiline—Nervous system disorder—Docetaxel—skin cancer	0.000205	0.00107	CcSEcCtD
Maprotiline—Pruritus—Fluorouracil—skin cancer	0.000204	0.00107	CcSEcCtD
Maprotiline—Thrombocytopenia—Docetaxel—skin cancer	0.000204	0.00107	CcSEcCtD
Maprotiline—Tachycardia—Docetaxel—skin cancer	0.000204	0.00107	CcSEcCtD
Maprotiline—Skin disorder—Docetaxel—skin cancer	0.000203	0.00106	CcSEcCtD
Maprotiline—Vomiting—Temozolomide—skin cancer	0.000199	0.00104	CcSEcCtD
Maprotiline—Rash—Temozolomide—skin cancer	0.000198	0.00103	CcSEcCtD
Maprotiline—Diarrhoea—Fluorouracil—skin cancer	0.000198	0.00103	CcSEcCtD
Maprotiline—Dermatitis—Temozolomide—skin cancer	0.000198	0.00103	CcSEcCtD
Maprotiline—Headache—Temozolomide—skin cancer	0.000196	0.00103	CcSEcCtD
Maprotiline—Hypotension—Docetaxel—skin cancer	0.000195	0.00102	CcSEcCtD
Maprotiline—Dizziness—Fluorouracil—skin cancer	0.000191	0.001	CcSEcCtD
Maprotiline—Insomnia—Docetaxel—skin cancer	0.000189	0.000987	CcSEcCtD
Maprotiline—Paraesthesia—Docetaxel—skin cancer	0.000187	0.00098	CcSEcCtD
Maprotiline—Nausea—Temozolomide—skin cancer	0.000186	0.000975	CcSEcCtD
Maprotiline—Somnolence—Docetaxel—skin cancer	0.000185	0.00097	CcSEcCtD
Maprotiline—Vomiting—Fluorouracil—skin cancer	0.000184	0.000961	CcSEcCtD
Maprotiline—Dyspepsia—Docetaxel—skin cancer	0.000184	0.000961	CcSEcCtD
Maprotiline—Rash—Fluorouracil—skin cancer	0.000182	0.000953	CcSEcCtD
Maprotiline—Dermatitis—Fluorouracil—skin cancer	0.000182	0.000952	CcSEcCtD
Maprotiline—Headache—Fluorouracil—skin cancer	0.000181	0.000947	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Docetaxel—skin cancer	0.00018	0.000942	CcSEcCtD
Maprotiline—Fatigue—Docetaxel—skin cancer	0.00018	0.000941	CcSEcCtD
Maprotiline—Constipation—Docetaxel—skin cancer	0.000178	0.000933	CcSEcCtD
Maprotiline—Feeling abnormal—Docetaxel—skin cancer	0.000172	0.000899	CcSEcCtD
Maprotiline—Nausea—Fluorouracil—skin cancer	0.000172	0.000898	CcSEcCtD
Maprotiline—Gastrointestinal pain—Docetaxel—skin cancer	0.000171	0.000892	CcSEcCtD
Maprotiline—Body temperature increased—Docetaxel—skin cancer	0.000165	0.000863	CcSEcCtD
Maprotiline—Abdominal pain—Docetaxel—skin cancer	0.000165	0.000863	CcSEcCtD
Maprotiline—Asthenia—Docetaxel—skin cancer	0.00015	0.000783	CcSEcCtD
Maprotiline—Pruritus—Docetaxel—skin cancer	0.000148	0.000772	CcSEcCtD
Maprotiline—ABCB1—lymph node—skin cancer	0.000145	0.00222	CbGeAlD
Maprotiline—Diarrhoea—Docetaxel—skin cancer	0.000143	0.000747	CcSEcCtD
Maprotiline—Dizziness—Docetaxel—skin cancer	0.000138	0.000722	CcSEcCtD
Maprotiline—Vomiting—Docetaxel—skin cancer	0.000133	0.000694	CcSEcCtD
Maprotiline—Rash—Docetaxel—skin cancer	0.000132	0.000688	CcSEcCtD
Maprotiline—Dermatitis—Docetaxel—skin cancer	0.000131	0.000687	CcSEcCtD
Maprotiline—Headache—Docetaxel—skin cancer	0.000131	0.000684	CcSEcCtD
Maprotiline—Nausea—Docetaxel—skin cancer	0.000124	0.000648	CcSEcCtD
Maprotiline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	5.99e-06	0.00104	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PTCH1—skin cancer	5.99e-06	0.00104	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—SMO—skin cancer	5.99e-06	0.00104	CbGpPWpGaD
Maprotiline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	5.97e-06	0.00104	CbGpPWpGaD
Maprotiline—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	5.97e-06	0.00103	CbGpPWpGaD
Maprotiline—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	5.96e-06	0.00103	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PTGER4—skin cancer	5.94e-06	0.00103	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—SHH—skin cancer	5.94e-06	0.00103	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PTGER4—skin cancer	5.93e-06	0.00103	CbGpPWpGaD
Maprotiline—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	5.91e-06	0.00102	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PTGER4—skin cancer	5.91e-06	0.00102	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—RASA1—skin cancer	5.9e-06	0.00102	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PTGER4—skin cancer	5.89e-06	0.00102	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PTGER4—skin cancer	5.83e-06	0.00101	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SUFU—skin cancer	5.74e-06	0.000994	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—GLI2—skin cancer	5.68e-06	0.000985	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PTCH1—skin cancer	5.63e-06	0.000975	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—SMO—skin cancer	5.63e-06	0.000975	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—SHH—skin cancer	5.61e-06	0.000972	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—GLI2—skin cancer	5.59e-06	0.000969	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—GLI2—skin cancer	5.58e-06	0.000967	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—RASA1—skin cancer	5.57e-06	0.000965	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—GLI2—skin cancer	5.56e-06	0.000964	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—GLI2—skin cancer	5.54e-06	0.000961	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—GLI2—skin cancer	5.49e-06	0.000951	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PTGER4—skin cancer	5.48e-06	0.000949	CbGpPWpGaD
Maprotiline—HTR2A—SIDS Susceptibility Pathways—IL6—skin cancer	5.45e-06	0.000945	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MC1R—skin cancer	5.42e-06	0.000939	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—SHH—skin cancer	5.37e-06	0.00093	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	5.36e-06	0.000928	CbGpPWpGaD
Maprotiline—CHRM2—SIDS Susceptibility Pathways—IL6—skin cancer	5.35e-06	0.000928	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—GLI1—skin cancer	5.34e-06	0.000926	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—RASA1—skin cancer	5.34e-06	0.000925	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MC1R—skin cancer	5.33e-06	0.000924	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MC1R—skin cancer	5.32e-06	0.000922	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PTCH1—skin cancer	5.32e-06	0.000921	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—SMO—skin cancer	5.32e-06	0.000921	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MC1R—skin cancer	5.31e-06	0.000919	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MC1R—skin cancer	5.29e-06	0.000916	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—GLI1—skin cancer	5.26e-06	0.000911	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—GLI1—skin cancer	5.25e-06	0.000909	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MC1R—skin cancer	5.24e-06	0.000908	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—GLI1—skin cancer	5.23e-06	0.000906	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PLIN2—skin cancer	5.22e-06	0.000904	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—GLI1—skin cancer	5.21e-06	0.000903	CbGpPWpGaD
Maprotiline—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	5.19e-06	0.000899	CbGpPWpGaD
Maprotiline—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	5.17e-06	0.000897	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PTGER4—skin cancer	5.17e-06	0.000897	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—GLI1—skin cancer	5.16e-06	0.000894	CbGpPWpGaD
Maprotiline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	5.16e-06	0.000894	CbGpPWpGaD
Maprotiline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	5.14e-06	0.000891	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—SMO—skin cancer	5.09e-06	0.000882	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PTCH1—skin cancer	5.09e-06	0.000882	CbGpPWpGaD
Maprotiline—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	5.08e-06	0.00088	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SUFU—skin cancer	5.07e-06	0.000878	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SUFU—skin cancer	4.98e-06	0.000864	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SUFU—skin cancer	4.97e-06	0.000862	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SUFU—skin cancer	4.96e-06	0.000859	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PTGER4—skin cancer	4.96e-06	0.000859	CbGpPWpGaD
Maprotiline—DRD2—Circadian rythm related genes—TP53—skin cancer	4.94e-06	0.000857	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SUFU—skin cancer	4.94e-06	0.000856	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PLIN2—skin cancer	4.92e-06	0.000852	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SUFU—skin cancer	4.89e-06	0.000848	CbGpPWpGaD
Maprotiline—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.86e-06	0.000842	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—FOXO4—skin cancer	4.84e-06	0.000839	CbGpPWpGaD
Maprotiline—CHRM1—Circadian rythm related genes—TP53—skin cancer	4.84e-06	0.000838	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—FOXO4—skin cancer	4.57e-06	0.000792	CbGpPWpGaD
Maprotiline—SLC6A3—Neuronal System—HRAS—skin cancer	4.53e-06	0.000785	CbGpPWpGaD
Maprotiline—DRD2—Circadian rythm related genes—IL6—skin cancer	4.53e-06	0.000784	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—ENO2—skin cancer	4.51e-06	0.000781	CbGpPWpGaD
Maprotiline—CHRM1—Circadian rythm related genes—IL6—skin cancer	4.43e-06	0.000767	CbGpPWpGaD
Maprotiline—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.41e-06	0.000764	CbGpPWpGaD
Maprotiline—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.4e-06	0.000762	CbGpPWpGaD
Maprotiline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.38e-06	0.00076	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—FOXO4—skin cancer	4.38e-06	0.000758	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SHH—skin cancer	4.38e-06	0.000758	CbGpPWpGaD
Maprotiline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.37e-06	0.000757	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—RASA1—skin cancer	4.35e-06	0.000754	CbGpPWpGaD
Maprotiline—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.22e-06	0.000731	CbGpPWpGaD
Maprotiline—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.21e-06	0.000729	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CSPG4—skin cancer	4.21e-06	0.000729	CbGpPWpGaD
Maprotiline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.2e-06	0.000727	CbGpPWpGaD
Maprotiline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	4.18e-06	0.000725	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PLIN2—skin cancer	4.17e-06	0.000722	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTCH1—skin cancer	4.15e-06	0.000719	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SMO—skin cancer	4.15e-06	0.000719	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTGER4—skin cancer	4.04e-06	0.0007	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CSPG4—skin cancer	3.96e-06	0.000687	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SHH—skin cancer	3.86e-06	0.000669	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RASA1—skin cancer	3.84e-06	0.000665	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SHH—skin cancer	3.8e-06	0.000659	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SHH—skin cancer	3.79e-06	0.000657	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SHH—skin cancer	3.78e-06	0.000655	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RASA1—skin cancer	3.78e-06	0.000654	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RASA1—skin cancer	3.77e-06	0.000653	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SHH—skin cancer	3.77e-06	0.000653	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RASA1—skin cancer	3.76e-06	0.000651	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RASA1—skin cancer	3.74e-06	0.000649	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SHH—skin cancer	3.73e-06	0.000647	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RASA1—skin cancer	3.71e-06	0.000643	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SMO—skin cancer	3.66e-06	0.000635	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTCH1—skin cancer	3.66e-06	0.000635	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SMO—skin cancer	3.6e-06	0.000624	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTCH1—skin cancer	3.6e-06	0.000624	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SMO—skin cancer	3.6e-06	0.000623	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTCH1—skin cancer	3.6e-06	0.000623	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.59e-06	0.000621	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTCH1—skin cancer	3.58e-06	0.000621	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SMO—skin cancer	3.58e-06	0.000621	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTCH1—skin cancer	3.57e-06	0.000619	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SMO—skin cancer	3.57e-06	0.000619	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—FOXO4—skin cancer	3.57e-06	0.000618	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTGER4—skin cancer	3.56e-06	0.000618	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SMO—skin cancer	3.54e-06	0.000613	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTCH1—skin cancer	3.54e-06	0.000613	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTGER4—skin cancer	3.51e-06	0.000608	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTGER4—skin cancer	3.5e-06	0.000607	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTGER4—skin cancer	3.49e-06	0.000605	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTGER4—skin cancer	3.48e-06	0.000603	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTGER4—skin cancer	3.44e-06	0.000597	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CSPG4—skin cancer	3.36e-06	0.000582	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TERT—skin cancer	3.23e-06	0.00056	CbGpPWpGaD
Maprotiline—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.19e-06	0.000552	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—FOXO4—skin cancer	3.15e-06	0.000546	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—FOXO4—skin cancer	3.1e-06	0.000537	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—FOXO4—skin cancer	3.09e-06	0.000536	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—FOXO4—skin cancer	3.08e-06	0.000534	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—FOXO4—skin cancer	3.07e-06	0.000532	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TERT—skin cancer	3.05e-06	0.000529	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—FOXO4—skin cancer	3.04e-06	0.000527	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TERT—skin cancer	2.92e-06	0.000507	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ENO2—skin cancer	2.86e-06	0.000496	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—NRAS—skin cancer	2.72e-06	0.000472	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ENO2—skin cancer	2.69e-06	0.000467	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—ERCC2—skin cancer	2.62e-06	0.000454	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—NRAS—skin cancer	2.57e-06	0.000446	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—BRAF—skin cancer	2.56e-06	0.000444	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—NRAS—skin cancer	2.46e-06	0.000427	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—BRAF—skin cancer	2.42e-06	0.000419	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TERT—skin cancer	2.38e-06	0.000413	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—KRAS—skin cancer	2.34e-06	0.000406	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—BRAF—skin cancer	2.32e-06	0.000401	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ENO2—skin cancer	2.28e-06	0.000396	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—KRAS—skin cancer	2.21e-06	0.000384	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—KRAS—skin cancer	2.12e-06	0.000367	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TERT—skin cancer	2.1e-06	0.000364	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TERT—skin cancer	2.07e-06	0.000359	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TERT—skin cancer	2.07e-06	0.000358	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TERT—skin cancer	2.06e-06	0.000357	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TERT—skin cancer	2.05e-06	0.000356	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TERT—skin cancer	2.03e-06	0.000352	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—NRAS—skin cancer	2.01e-06	0.000348	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—HRAS—skin cancer	1.99e-06	0.000345	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—IL6—skin cancer	1.91e-06	0.00033	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—BRAF—skin cancer	1.89e-06	0.000327	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—HRAS—skin cancer	1.88e-06	0.000326	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—HRAS—skin cancer	1.8e-06	0.000312	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—IL6—skin cancer	1.8e-06	0.000312	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.79e-06	0.000309	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—NRAS—skin cancer	1.77e-06	0.000307	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.74e-06	0.000302	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—NRAS—skin cancer	1.74e-06	0.000301	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—NRAS—skin cancer	1.73e-06	0.000301	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—NRAS—skin cancer	1.73e-06	0.0003	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.73e-06	0.000299	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—IL6—skin cancer	1.72e-06	0.000299	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—NRAS—skin cancer	1.71e-06	0.000297	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—BRAF—skin cancer	1.67e-06	0.000289	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ERCC2—skin cancer	1.66e-06	0.000288	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—BRAF—skin cancer	1.64e-06	0.000284	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—BRAF—skin cancer	1.64e-06	0.000283	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—BRAF—skin cancer	1.63e-06	0.000282	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—BRAF—skin cancer	1.62e-06	0.000282	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—BRAF—skin cancer	1.61e-06	0.000279	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—NRAS—skin cancer	1.61e-06	0.000279	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—skin cancer	1.57e-06	0.000272	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ERCC2—skin cancer	1.57e-06	0.000271	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—KRAS—skin cancer	1.53e-06	0.000264	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NRAS—skin cancer	1.52e-06	0.000263	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—KRAS—skin cancer	1.5e-06	0.00026	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—KRAS—skin cancer	1.5e-06	0.000259	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—KRAS—skin cancer	1.49e-06	0.000259	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—KRAS—skin cancer	1.49e-06	0.000258	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—KRAS—skin cancer	1.47e-06	0.000255	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.47e-06	0.000255	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NRAS—skin cancer	1.46e-06	0.000252	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—IL6—skin cancer	1.41e-06	0.000244	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—skin cancer	1.38e-06	0.00024	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ERCC2—skin cancer	1.33e-06	0.00023	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—skin cancer	1.31e-06	0.000227	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—HRAS—skin cancer	1.3e-06	0.000225	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—HRAS—skin cancer	1.28e-06	0.000221	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—HRAS—skin cancer	1.27e-06	0.000221	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—HRAS—skin cancer	1.27e-06	0.00022	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—HRAS—skin cancer	1.26e-06	0.000219	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—HRAS—skin cancer	1.25e-06	0.000217	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—skin cancer	1.25e-06	0.000217	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—skin cancer	1.24e-06	0.000215	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—skin cancer	1.23e-06	0.000213	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—skin cancer	1.22e-06	0.000212	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—skin cancer	1.22e-06	0.000211	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—skin cancer	1.21e-06	0.00021	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—skin cancer	1.21e-06	0.00021	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—skin cancer	1.2e-06	0.000208	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NRAS—skin cancer	1.19e-06	0.000206	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—HRAS—skin cancer	1.18e-06	0.000204	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—skin cancer	1.16e-06	0.000201	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—skin cancer	1.13e-06	0.000195	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—skin cancer	1.11e-06	0.000193	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—HRAS—skin cancer	1.11e-06	0.000193	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—HRAS—skin cancer	1.06e-06	0.000184	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—skin cancer	1.06e-06	0.000184	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NRAS—skin cancer	1.05e-06	0.000181	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NRAS—skin cancer	1.03e-06	0.000178	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NRAS—skin cancer	1.03e-06	0.000178	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NRAS—skin cancer	1.02e-06	0.000178	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NRAS—skin cancer	1.02e-06	0.000177	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—skin cancer	1.02e-06	0.000177	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—skin cancer	1.02e-06	0.000177	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NRAS—skin cancer	1.01e-06	0.000175	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—skin cancer	9.96e-07	0.000173	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—skin cancer	9.39e-07	0.000163	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—skin cancer	9.07e-07	0.000157	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—skin cancer	9.01e-07	0.000156	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—skin cancer	8.87e-07	0.000154	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—skin cancer	8.85e-07	0.000153	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—skin cancer	8.82e-07	0.000153	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—skin cancer	8.79e-07	0.000152	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—skin cancer	8.7e-07	0.000151	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—HRAS—skin cancer	8.68e-07	0.00015	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—skin cancer	8.31e-07	0.000144	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—skin cancer	8.01e-07	0.000139	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—skin cancer	7.95e-07	0.000138	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—skin cancer	7.88e-07	0.000137	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—skin cancer	7.86e-07	0.000136	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—skin cancer	7.84e-07	0.000136	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—skin cancer	7.81e-07	0.000135	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—skin cancer	7.74e-07	0.000134	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—HRAS—skin cancer	7.66e-07	0.000133	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—HRAS—skin cancer	7.54e-07	0.000131	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—HRAS—skin cancer	7.52e-07	0.00013	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—HRAS—skin cancer	7.49e-07	0.00013	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—HRAS—skin cancer	7.47e-07	0.000129	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—HRAS—skin cancer	7.4e-07	0.000128	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—skin cancer	7.33e-07	0.000127	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—skin cancer	7.21e-07	0.000125	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—skin cancer	7.2e-07	0.000125	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—skin cancer	7.17e-07	0.000124	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—skin cancer	7.15e-07	0.000124	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—skin cancer	7.08e-07	0.000123	CbGpPWpGaD
